OrthoPediatrics Corp. KIDS R2KR3KPHARMA
Company Overview
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Why Investors Should Care
Revenue has grown at a 22.5% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.32.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $236.35M (+15.4% YoY); net profit $-39.65M.
- Trailing 12 Months Year-on-year growth — revenue +15.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 22.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 22.52% |
| 1 Year: | 15.40% |
Stock Price Performance
| 1 Year: | +11.55% |
| 6 Months: | +24.16% |
| 3 Months: | +22.33% |
| 1 Month: | -1.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)43.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 22.5% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KIDS OrthoPediatrics Corp. R2KR3KPHARMA | 22.41 | -13.34 | $585.12M | 0.00% | -8.49% | -11.36% | 22.52% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 9.76M | 11.80M | 12.38M | 11.68M | 12.09M | 15.08M | 15.82M | 14.57M | 14.66M | 18.20M | 20.74M | 18.95M | 16.36M | 13.59M | 22.20M | 18.92M | 21.46M | 26.70M | 25.08M | 24.81M | 23.42M | 32.93M | 34.95M | 31.59M | 39.56M | 39.97M | 44.69M | 52.80M | 54.57M | 52.41M | 61.08M | 61.25M | 59.36M | 70.51M |
| Gross Profit | - | - | 7.16M | - | 7.42M | 8.71M | 9.49M | 8.83M | 8.92M | 11.27M | 11.98M | 10.51M | 10.65M | 13.62M | 15.89M | 14.45M | 12.21M | 10.06M | 17.64M | 15.12M | 16.32M | 20.44M | 18.55M | 18.08M | 18.57M | 24.98M | 25.89M | 23.56M | 30.02M | 30.95M | 32.17M | 40.80M | 40.06M | 38.26M | 44.02M | 45.27M | 43.39M | 52.37M |
| Operating Income | -1.49M | -865.00K | -524.00K | -3.25M | -837.00K | -677.00K | -754.00K | -4.20M | -4.39M | -2.12M | -1.17M | -1.87M | -2.72M | -1.79M | -1.54M | -3.03M | -4.50M | -7.02M | -2.50M | -12.74M | -5.97M | -2.85M | -3.64M | -5.56M | -6.39M | -3.74M | -6.96M | -8.59M | -5.59M | -4.51M | -9.72M | -5.67M | -5.57M | -10.98M | -10.66M | -9.43M | -8.34M | -4.07M |
| Net Income | -1.80M | -288.00K | -846.00K | -3.63M | -1.28M | -1.27M | -1.54M | -4.84M | -5.00M | -2.69M | -1.86M | -2.47M | -3.02M | -2.62M | -2.66M | -5.43M | -4.95M | -9.45M | -4.54M | -14.01M | -10.38M | -3.76M | -2.20M | - | -9.10M | -333.00K | 18.54M | -6.81M | -2.89M | -4.59M | -7.80M | -6.03M | -7.92M | -10.66M | -7.11M | -11.77M | -10.69M | -7.16M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.30 | -0.54 | -0.24 | -0.73 | -0.54 | -0.19 | -0.11 | 0.00 | -0.47 | -0.02 | 0.87 | -0.30 | -0.13 | -0.20 | -0.34 | -0.26 | -0.34 | -0.46 | -0.30 | -0.50 | -0.45 | -0.30 |
| R&D Expense | - | - | 501.00K | - | 687.00K | 668.00K | 1.13M | - | 1.22M | 1.11M | 1.12M | - | 1.21M | 1.23M | 1.40M | - | 1.26M | 881.00K | 1.08M | - | 1.31M | 1.32M | 1.30M | - | 2.03M | 1.75M | 2.21M | 2.45M | 2.97M | 2.56M | 3.00M | 2.54M | 2.58M | 2.35M | 2.16M | 2.33M | 2.23M | 2.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.00M | 37.30M | 45.62M | 57.56M | 72.55M | 71.08M | 98.05M | 122.29M | 148.73M | 204.73M | 236.35M |
| Gross Profit | 21.64M | 26.37M | 34.45M | 42.68M | 54.62M | 55.03M | 73.40M | 90.66M | 111.25M | 148.60M | 172.66M |
| Operating Income | -6.59M | -6.13M | -6.47M | -9.55M | -9.08M | -26.75M | -18.02M | -25.40M | -26.75M | -35.01M | -39.24M |
| Net Income | -7.89M | -6.57M | -8.93M | -12.03M | -13.73M | -32.94M | -16.26M | 1.26M | -20.97M | -37.82M | -39.65M |
| Diluted EPS | - | - | - | - | -0.94 | -1.82 | -0.84 | 0.06 | -0.92 | -1.64 | -1.69 |
| R&D Expense | 1.79M | 2.22M | 3.42M | 4.73M | 5.75M | 5.27M | 5.54M | 8.45M | 10.89M | 11.03M | 9.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 30.68M | 82.30M | 112.11M | 182.15M | 320.41M | 304.27M | 427.73M | 438.75M | 473.21M | 508.63M |
| Total Equity | -42.65M | -54.11M | -65.31M | 47.49M | 81.73M | 142.36M | 234.77M | 225.37M | 378.65M | 377.02M | 354.57M | 346.60M |
| Cash & Equivalents | 6.58M | 3.88M | 1.61M | 42.58M | 60.69M | 70.78M | 28.76M | 7.64M | 8.99M | 31.05M | 43.82M | 19.56M |
| Long Term Debt | - | - | 17.43M | 25.34M | 21.16M | 26.07M | 1.04M | 907.00K | 763.00K | 9.91M | 72.96M | 99.82M |
| Total Liabilities | - | - | 24.68M | 34.81M | 30.37M | 39.79M | 85.64M | 78.91M | 49.08M | 61.72M | 118.64M | 162.03M |
| Current Liabilities | - | - | 7.25M | 9.47M | 9.22M | 13.66M | 35.03M | 29.71M | 30.87M | 41.67M | 33.96M | 46.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -892.00K | -1.12M | -7.22M | -15.58M | -17.77M | -18.53M | -13.06M | -21.77M | -27.05M | -27.05M | -4.85M |
| Investing Cash Flow | -1.71M | -4.75M | -6.54M | -5.96M | -61.92M | -69.69M | -7.41M | -113.37M | 41.68M | -13.16M | -43.63M |
| Financing Cash Flow | -98.00K | 3.60M | 54.73M | 39.66M | 91.02M | 46.73M | 6.00K | 135.97M | 7.30M | 53.13M | 23.98M |
| Capital Expenditure | -2.21M | -4.35M | -5.21M | -5.25M | -11.82M | -10.50M | -8.10M | -10.03M | -16.88M | -14.26M | -11.11M |
| Free Cash Flow | -3.10M | -5.47M | -12.42M | -20.84M | -29.59M | -29.03M | -21.17M | -31.80M | -43.92M | -41.31M | -15.96M |
| Dividends Paid | 0 | 0 | 5.96M | 0 | 0 | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 69.8% | 70.7% | 75.5% | 74.2% | 75.3% | 77.4% | 74.9% | 74.1% | 74.8% | 72.6% | 73.1% |
| Operating Margin % | -21.3% | -16.4% | -14.2% | -16.6% | -12.5% | -37.6% | -18.4% | -20.8% | -18.0% | -17.1% | -16.6% |
| Net Margin % | -25.5% | -17.6% | -19.6% | -20.9% | -18.9% | -46.3% | -16.6% | 1.0% | -14.1% | -18.5% | -16.8% |
| ROE % | 14.6% | 10.1% | -18.8% | -14.7% | -9.6% | -14.0% | -7.2% | 0.3% | -5.6% | -10.7% | -11.4% |
| ROCE % | - | -26.2% | -8.9% | -9.3% | -5.4% | -9.4% | -6.6% | -6.4% | -6.7% | -8.0% | -8.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Brown Advisory Inc. | 6.43% | 1.68M | $39.71M |
| 2 | Blackrock Inc. | 4.87% | 1.27M | $30.10M |
| 3 | Braidwell LP | 4.21% | 1.10M | $26.02M |
| 4 | Granahan Investment Management LLC | 4.16% | 1.09M | $25.68M |
| 5 | Millennium Management Llc | 3.13% | 816.83K | $19.32M |
| 6 | Wellington Management Group, LLP | 3.04% | 794.31K | $18.79M |
| 7 | Vanguard Capital Management LLC | 2.89% | 755.62K | $17.87M |
| 8 | Soleus Capital Management, L.P. | 2.80% | 732.14K | $17.32M |
| 9 | Morgan Stanley | 2.66% | 693.39K | $16.40M |
| 10 | Wasatch Advisors LP | 1.98% | 515.68K | $12.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KIDS
Take Stock in Children angel mentor changes lives in Escambia County - WEAR-TV
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQX0c3ejdYV0NVbVVqN2xGY2pUay15V2hPMFRlcW51QlFaQ3BNUWlzb2RZZUZQV29XeFpUdUlFNFdfUldEcTBzUWFVbi0tRFFIY0J5WXkzOFZrRTJFMmZjTVF1YmlPcDhEeVlUOHBXUzJMUUZVbFRzel9PR0JGUzdWRDNpYk1yNElHNzIxV2…
Jim Cramer: 'Put This Stock Away, Give It to Your Kids' - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOc1EweUN2MDZfSTJEZUtIakhKQ01sT2ttRjRocHN4YkNXRVQzM3pQWDFxUzAyWDZUUHd2SzNRTEswX3JNbEExdlkyUU5YM2puX3hLX3NpT2lpZ2hUY1h3TTJwbjdYeVRWNXphTzVCWVZNVHJZdzI5U1lVdXBmbmg2WlpnbGQ4VklUd0NEWW…
Cramer's lightning round: Buy SpaceX and 'give it to your kids' - CNBC
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPTE9nSDlkUTdfSnRMWG1iT203XzFZMlk2Rl9OeFlVeWhSbHR2UDgzeUJBak40SXdydGN1ZlZTMmtBUDBwVmlQWU9HYjB6bmY5dkJrNUY4M0xtZi1MQmRGWUFZQThkRTRYN0hjX3F0VW1KeXVjRDlyRldkbVdtbk9WV3BaZVJMZW05Ql9NdG…
WATCH: Trump officially launches Trump Accounts for kids, ringing Wall Street opening bell - PBS
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNRGhiWENIOFZWSmo3aEJNQjhRZjlmYWZCQzFQcEticTZYY0JvNDFGRVpIcGpVcU9mZWtGZkJMTXhPOXBQRzFRZEEtYXRuWm9HU09hWVdtNjl5UkpITEcwcWFtT2M1Rl80ZEpOWUc3ZktFdXZUUDZHOVRabUNlZC1CNHhLYTBvb0ExeDdmWW…
OrthoPediatrics(KIDS.US) 10% Shareholder Sells US$7.76 Million in Common Stock - Moomoo
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOeHVwSFR5N05QWmdRcWREczZiMDRfWEt1al9UZVFyUVJuUU45R01pLTVJbFBWREFwMXBoVmFtald0UHo1aHFtTnY2YjMyV3I3WGpLV2h2M3NscWN0dG1KdmVIbWtNWEJfM1c0SWdhbFBzVUtxOGlmU29sUE1PQXkzcGwxMDJkdjdDN3A2YT…
Kids Are Home for Summer, Stock Up on Supplies This Prime Day (2026) - Bon Appétit: Recipes, Cooking, Entertaining, Restaurants | Bon Appétit
<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE1ZMk5UdmlRczVCYzkyNXhGam1lbnVBZHhCamVBQWhoZUtCcFktMnhVVHA0ODBNX1RISHdHeXppZnpYTlJFQ29fcmlaU3l6NldvWDlmS3NMdjRDcng2RUpZU000azNGbkVQM3c?oc=5" target="_blank">Kids Are Home for Summer…
KIDS — Frequently Asked Questions
What is the current share price of OrthoPediatrics Corp. (KIDS)?
As of 2026-09-07 16:24 PDT, OrthoPediatrics Corp. (KIDS) trades at $22.41 on NasdaqGM. Its 52-week range is $14.64 to $26.50.
What is the market capitalisation of KIDS?
OrthoPediatrics Corp. (KIDS) has a market capitalisation of $585.12M on NasdaqGM.
What is the P/E ratio of KIDS?
KIDS trades at a trailing price-to-earnings (P/E) ratio of -13.34. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.73.
What is the return on equity (ROE) of KIDS?
KIDS has a return on equity (ROE) of -11.36%. Its return on capital employed (ROCE) is -8.49%.
Is KIDS a good stock to buy?
This page provides a data-driven analysis of OrthoPediatrics Corp. (KIDS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.